- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Transcript
Recently, the FDA approved a sixth pegfilgrastim biosimilar (Fresenius Kabi’s Stimufend) and a fourth bevacizumab biosimilar (Celltrion Healthcare’s Vegzelma), the fourth and fifth oncology biosimilars to be approved in 2022 so far. What do these approvals tell you about the current status of the oncology biosimilar space?
Alvarnas: So, the key thing about biosimilars is when the concept first came, a lot of us were thinking, "What a quaint idea." And I think there was a lot of skepticism as to whether or not this would translate into something real. I think with the new approvals, what you see is this is something real—that we have biosimilars for a significant number of meaningful oncology products.
As we see multiple biosimilars enter into a competitive race with the originator molecule, then you get to a market-competitive model that can begin to address issues of drug pricing that can foster better stewardship as well as better engagement of clinicians as they think through their purchasing contracts, their supply chains, and clinical care pathways.
So, when we look at the portfolio of all the approved biosimilars, this constitutes something real. This constitutes a path forward toward embracing deeper models of value that don't compromise patient outcomes and don't compromise patient access by ensuring that we can be both value centered and yet extraordinary stewards of great care.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
